Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.53 |
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10396219 | 0.84 | PTPN1 (0.50) | PTPN1GSK3BKDM4ERAB9AALDH1A1 | |
| SCHEMBL9409754 | 0.82 | PTPN1 (0.65) | PTPN1GSK3BHPGDSKDM4EALDH1A1 | |
| SCHEMBL980175 | 0.81 | CYP2C19 (0.59) | PTPN1KDM4ERAB9AALDH1A1HPGD | |
| SCHEMBL9624082 | 0.78 | KMT2A (0.59) | PTPN1KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL9732721 | 0.78 | BACE1 (0.57) | PTPN1GSK3BRAB9AHPGDKMT2A | |
| SCHEMBL29758522 | 0.74 | PTPN1 (0.57) | PTPN1GSK3BHPGDSKDM4ERAB9A | |
| SCHEMBL166468 | 0.74 | PTPN1 (0.57) | PTPN1GSK3BHPGDSKDM4ERAB9A | |
| SCHEMBL1701142 | 0.74 | PTPN1 (0.57) | PTPN1GSK3BKDM4ERAB9AALDH1A1 | |
| SCHEMBL31519376 | 0.74 | ALDH1A1 (0.64) | PTPN1GSK3BHPGDSKDM4EALDH1A1 | |
| SCHEMBL29845700 | 0.74 | PTPN1 (0.57) | PTPN1GSK3BKDM4ERAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | THE BINDING SITE GROUP LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4675278-A2 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-12461108-B2 | Mass spectrometry kit including a cross-linked antibody or fragment thereof | THE BINDING SITE GROUP LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| US-20230391851-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3420362-B1 | ANTIBODIES | THE BINDING SITE GROUP LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-20230080943-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | THE BINDING SITE GROUP LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-4123308-A1 | MASS SPECTROMETRY KIT | The Binding Site Group Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3420361-B1 | MASS SPECTROMETRY KIT | THE BINDING SITE GROUP LTD (GB) | 2023-01-04 | — | — | EP | disclosed |
| US-20040126838-A1 | Follicle stimulating hormone: remodeling and glycoconjugation of FSH | NEOSE TECHNOLOGIES, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040001892-A1 | Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-01 | — | — | US | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0562624-A2 | Stabilization of functional proteins | Modrovich, Ivan E. (US) | 1993-09-29 | — | — | EP | disclosed |
| US-4202775-A | CROSSLINKABLE ETHYLENICALLY UNSATURATED POROUS COPOLYMER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | IGLV6-57, IGSF11, FCGR3B | PTPN1 466/4885GSK3B 4491/4885HPGDS 2393/4885 |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | PTPN1 1110/4885GSK3B 4541/4885HPGDS 173/4885 |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | IFNG, IFNAR1, IRF3 | PTPN1 463/4885GSK3B 3333/4885HPGDS 288/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | PTPN1 1812/4885GSK3B 4308/4885HPGDS 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.